| Document |
Document Title |
|
WO/2005/070427A1 |
The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative ther...
|
|
WO/2005/070113A2 |
The present invention discloses compounds of formula (I), (II), (III), or (IV), or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: formulas (I), (II), (III), (IV), which exhibit antibacterial properties. The present ...
|
|
WO/2005/068485A1 |
The present invention relates to the pharmaceutical composition and health care food comprising flavonoid compounds isolated from the extract of Sedum sarmentosum Bunge for preventing and treating hypertension. The flavonoid compounds of...
|
|
WO/2005/067919A1 |
The present invention discloses compounds of formulae I, II, III or IV or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I), (II), (III), (IV), which exhibit antibacterial properties. The present invention further relat...
|
|
WO/2005/067564A2 |
The present invention discloses compounds of formulaes I, II, III, or IV, or a 5 racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates to pharmace...
|
|
WO/2005/068484A1 |
The invention relates to complexes of specific flavonoid derivatives of formula (I), to preparations containing derivatives of this type, to corresponding methods for producting the flavonoid derivatives or preparations containing the la...
|
|
WO/2005/063263A1 |
The invention relates to novel derivatives of morphine-6-glucuronide, the preparation method thereof and the uses of same in therapy, for example, as analgesics.
|
|
WO/2005/061526A1 |
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formule (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compos...
|
|
WO/2005/061525A1 |
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions c...
|
|
WO/2005/060693A2 |
9-Desoxoerythromycin compounds of formula (I); wherein R1, R2, R3, R4 and R5 are as defined herein, are useful as prokinetic agents for treating disorders of gastric motility.
|
|
WO/2005/061524A2 |
The present invention provides an efficient process for the preparation of polymorphic Form I and II of clarithromycin. The process includes drying wet clarithromycin obtained after purification in the presence of nitrogen gas and in the...
|
|
WO/2005/054265A2 |
Macrolides particularly erythromycins and azithromycins, having O-mycaminosyl or O-angolosaminyl groups, particularly at the 5-position, are produced using a gene cassette comprising a combination of genes which, in an appropriate strain...
|
|
WO/2005/054267A1 |
The present invention relates to compounds of formula (1) and salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 is a glycosyl moiety, hydroxyl-protected acetate derivatives thereof or ami...
|
|
WO/2005/053650A1 |
An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multipar...
|
|
WO/2005/049598A1 |
The invention relates to novel hydrosoluble yellow colouring agents of general formula (I), wherein n is equal to 0 or 1, R1 is H or an alkyl group, R2 is H, a glucose group or a xyloglucose group. A method for preparing and using the in...
|
|
WO/2005/049632A1 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic ag...
|
|
WO/2005/049579A2 |
The present invention relates to immobilized N-substituted tricyclic 3-aminopyrazole compounds of Formula 1 as tools for the identification of bimolecular targets in cells of therapeutic significance, profiling the selectivity of compoun...
|
|
WO/2005/044834A1 |
A method for preparing a stabilized azithromycin composition comprising mixing azithromycin monohydrate and water to form a stabilized azithromycin composition having a water content from about 5 to about 15 weight percent, based on the ...
|
|
WO/2005/042554A1 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic ag...
|
|
WO/2005/042555A1 |
A tyrosinase activity inhibitor and an ameliorant for facial blood flow which each is highly safe; and a medicinal composition, food composition, or cosmetic preparation each containing these as active ingredients. The tyrosinase activit...
|
|
WO/2005/039500A2 |
The present invention provides methods for the isolation of a new group of actinomycetes and for the identification of members of this group based on characteristic nucleotide sequences and phylogenetic analyses. This group is phylogenet...
|
|
WO/2005/034846A2 |
Novel isolated and purified withanamides and withanolides are described. In particular, compounds from Withania somnifera fruit are the preferred source of the withanamides and withanolides, although they can be from other plant sources....
|
|
WO/2005/034856A2 |
The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic i...
|
|
WO/2005/036169A2 |
Fluorescent probes that have binding affinity to ribosome. The fluorescent probes are useful tools for identifying small molecules that bind to the 50S or 30S subunits of the bacterial and other ribosome inhibitors. These probes are also...
|
|
WO/2005/033123A1 |
Disclosed is a compound represented by the following general formula (I): (I) (wherein R1 represent a glycosyl group, a phosphoric acid group , or a cyclic phosphoric acid group bonded with R2; R2 represents -CH2OH, -CHO, -CH2NH2, -CH2-a...
|
|
WO/2005/030785A2 |
The invention relates to novel compounds of 5-thioxylose and, preferably, 5-thioxylopyranose-type derivatives. The invention also relates to the method of preparing said compounds and to the use of same as an active principle in medicame...
|
|
WO/2005/030233A1 |
An active oxygen scavenging agent; and a process for producing the same. In particular, an active oxygen scavenging agent comprising as an active ingredient a product of decomposition of anthocyanin pigment derived from acerola; and a pr...
|
|
WO/2005/030227A1 |
The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof, which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions com...
|
|
WO/2005/028493A1 |
Antimicrobial compounds are provided having the formula (Q): as well as tautomers, stereoisomers, pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating b...
|
|
WO/2005/028630A2 |
Disclosed herein are methods and compositions for modulation of gene expression, with single-gene specificity, in a human sized genome.
|
|
WO/2005/027828A2 |
This invention features a compound of the following formula: T-(-L-C)m, T is a transportophore, L is a bond or a linker having a molecular weight up to 240 dalton, C is a non-antibiotic therapeutic agent, and m is 1, 2, 3, 4, 5, 6, 7, or...
|
|
WO/2005/027622A1 |
It is intended to provide a flower color crossing method whereby a specific flower color is passed to the next generation of delphinium and a flower color crossing method whereby a dichromatic flower color is passed to the next generatio...
|
|
WO/2005/028492A1 |
The invention relates to a crystalline compound of 4'-demethyl-4'-phosphate-2',3'-bispentafluorophenoxyacetyl-4
',6'-ethylidene-β-D-epipodophyllotoxin glucoside in its free form or solvated with ethanol, advantageously provided in the f...
|
|
WO/2005/025490A2 |
A novel family of cyclic polyene natural products isolated from marine actinomycete strain CNQ 140 is provided. This novel strain of actinomycetes was obtained from a previously unstudied population of marine actinomycetes that reside in...
|
|
WO/2005/021567A1 |
The present invention relates to a process for regioselective O-alkylation of macrolide and azalide derivatives, specifically 11-0-alkyl derivatives represented by formula (I) (1) R1 wherein A is 14-membered macrolide derivative and 15-m...
|
|
WO/2005/021566A2 |
The invention relates to glucopyranosyloxy-pirazoles of formula (I), wherein R1 to R6 and R7a, R7b and R7c are defined in the claim 1, to the tautomers, stereoisomers, mixtures and the salts thereof, in particular the salts which are phy...
|
|
WO/2005/018577A2 |
Compounds of formula (I) and R1, R 2 R 3 and R 4 are as defined herein, are prokinetic agents and can be used to treat disorders of gastric motility.
|
|
WO/2005/018576A2 |
Compounds having the structure of formula I: wherein R1,R2,R3, R4, R5, and R6 are as defined herein, are prokinetic agents and can be used to treat disorders of gastric motility.
|
|
WO/2005/019238A1 |
Compounds represented by the general formula (1) or pharmaceutically acceptable salts thereof, effective in the prevention and/or treatment of infections with microbes: (1) (a) wherein R1 is hydrogen or straight-chain C1-6 alkylcarbonyl;...
|
|
WO/2005/016851A1 |
The invention relates to novel molecules and libraries thereof as well as methods for their production. Methods of producing the novel molecules include a. cleaving one or more of starting molecules into molecular subunits ; and b. assem...
|
|
WO/2005/012322A1 |
A process for producing erythromycin A 11,12-cyclic carbonate (compound (II)) from erythromycin A (compound (I)), which is shown by the reaction scheme, [Chemical formula 1] (I) → (II) the process comprising reacting erythromycin A wit...
|
|
WO/2005/012243A2 |
Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.
|
|
WO/2005/012321A1 |
A compound of the formula (I): wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionall...
|
|
WO/2005/011592A2 |
Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.
|
|
WO/2005/012242A2 |
This invention relates to to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of d...
|
|
WO/2005/012318A2 |
This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
|
|
WO/2005/010019A1 |
Crystalline 6-N-pyridylmethylamino-12,13-dihydro-2,10 -dihydroxy-12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,
4-c]carbazole-5,7(6H)-diones in the form of the free bases as represented by the general formula (I), pharmaceutically acc...
|
|
WO/2005/010018A1 |
6-N-Pyridylmethylamino-12,13-dihydro-2,10-dihydroxy- 12-β-D-glucopyranosyl-5H-indolo[2,3-a]pyrrolo[3,4-c]carba- zole-5,7(6H)-dione free bases (I) in the form of crystals; pharmaceutically acceptable salts of the same; or solvates thereo...
|
|
WO/2005/010017A1 |
A compound represented by the formula [I] (wherein R represents unsubstituted pyridyl, furyl, or thienyl; m is an integer of 1 to 3; G represents ß-D-glucopyranosyl; and the hydroxy substituents on the indolopyrrolocarbazole ring are lo...
|
|
WO/2005/010020A1 |
A compound represented by the formula [I] (wherein R represents unsubstituted pyridyl, furyl, or thienyl; m is an integer of 1 to 3; G represents β-D-glucopyranosyl; and the positions of the hydroxy substituents on the indolopyrrocarbaz...
|
